• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gyroscope Therapeutics raises $148M Series C

March 26, 2021 By Sean Whooley

Gyroscope TherapeuticsGyroscope Therapeutics announced today that it raised $148 million (£107.8 million) in a Series C financing round.

Forbion’s Growth Opportunities Fund led the round, while Sofinnova Investments, funds and accounts advised by T. Rowe Price, Tetragon Financial, Fosun Pharma, Cambridge Innovation Capital and Syncona, along with an undisclosed fund, contributed.

In conjunction with the financing, the company announced that Forbion general partner Wouter Joustra and Sofinnova general partner Maha Katabi were appointed to its board of directors.

London-based Gyroscope said in a news release that it plans to use the funds raised to advance the clinical development of GT005, the company’s investigational gene therapy designed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

GT005 has fast-track designation from the FDA and is currently being evaluated in Phase 2 clinical trials. Gyroscope said the financing round will also help the company advance its early-stage pipeline and its delivery technology, which includes the proprietary Orbit subretinal delivery system that provides precise delivery of therapeutics to the back of the eye.

“We are excited to welcome a new group of leading life sciences investors on our journey to deliver gene therapy beyond rare disease. Their investment in Gyroscope will allow us to continue building our portfolio of investigational gene therapies,” Gyroscope CEO Khurem Farooq said in the release. “We recently announced encouraging Phase I/II clinical trial data with our lead investigational gene therapy, GT005, that give us confidence in its potential as a treatment for geographic atrophy and are continuing to advance our Phase II clinical program.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic Tagged With: Gyroscope Therapeutics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS